NASDAQ:DCPH - Nasdaq - US24344T1016 - Common Stock - Currency: USD
Taking everything into account, DCPH scores 4 out of 10 in our fundamental rating. DCPH was compared to 556 industry peers in the Biotechnology industry. DCPH has a great financial health rating, but its profitability evaluates not so good. DCPH is valied quite expensively at the moment, while it does show a decent growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -45.24% | ||
ROE | -60.25% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 96.95% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Altman-Z | 7.32 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 4.19 | ||
Quick Ratio | 3.94 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
25.59
+0.02 (+0.08%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 12.65 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 7 | ||
P/tB | 7 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -45.24% | ||
ROE | -60.25% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 96.95% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 29.04% | ||
Cap/Sales | 0.32% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 4.19 | ||
Quick Ratio | 3.94 | ||
Altman-Z | 7.32 |